Related references
Note: Only part of the references are listed.Antipsychotic-induced Hdac2 transcription via NF-κB leads to synaptic and cognitive side effects
Daisuke Ibi et al.
NATURE NEUROSCIENCE (2017)
Genetic insights into the neurodevelopmental origins of schizophrenia
Rebecca Birnbaum et al.
NATURE REVIEWS NEUROSCIENCE (2017)
Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation, and Disrupts Memory Reconsolidation
Adam G. Walker et al.
NEUROPSYCHOPHARMACOLOGY (2017)
Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort
Anja P. Husa et al.
PSYCHIATRY RESEARCH (2017)
Targeting metabotropic glutamate receptors for novel treatments of schizophrenia
James Maksymetz et al.
MOLECULAR BRAIN (2017)
The safety profile of vorinostat suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies
Madeleine Duvic et al.
CANCER TREATMENT REVIEWS (2016)
Epigenetic Mechanisms of Serotonin Signaling
Terrell Holloway et al.
ACS CHEMICAL NEUROSCIENCE (2015)
Second-generation antipsychotic effect on cognition in patients with schizophrenia-a meta-analysis of randomized clinical trials
R. E. Nielsen et al.
ACTA PSYCHIATRICA SCANDINAVICA (2015)
Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia
Bruce J. Kinon et al.
BIOLOGICAL PSYCHIATRY (2015)
Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects
Yasmin Schmid et al.
BIOLOGICAL PSYCHIATRY (2015)
Antipsychotics and Amotivation
Gagan Fervaha et al.
NEUROPSYCHOPHARMACOLOGY (2015)
Metabotropic glutamate receptor 3 activation is required for long-term depression in medial prefrontal cortex and fear extinction
Adam G. Walker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment
Amr Ellaithy et al.
TRENDS IN NEUROSCIENCES (2015)
Targeting type-2 metabotropic glutamate receptors to protect vulnerable hippocampal neurons against ischemic damage
Marta Motolese et al.
MOLECULAR BRAIN (2015)
Epigenetic upregulation of metabotropic glutamate receptor 2 in the spinal cord attenuates oestrogen-induced visceral hypersensitivity
Dong-Yuan Cao et al.
GUT (2015)
Epigenetic Priming of Memory Updating during Reconsolidation to Attenuate Remote Fear Memories
Johannes Graeff et al.
CELL (2014)
Repeated treatment with electroconvulsive seizures induces HDAC2 expression and down-regulation of NMDA receptor-related genes through histone deacetylation in the rat frontal cortex
Hong Geun Park et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2014)
Lifetime use of antipsychotic medication and its relation to change of verbal learning and memory in midlife schizophrenia - An observational 9-year follow-up study
Anja P. Husa et al.
SCHIZOPHRENIA RESEARCH (2014)
mRNA expression profile of serotonin receptor subtypes and distribution of serotonergic terminations in marmoset brain
Rammohan Shukla et al.
FRONTIERS IN NEURAL CIRCUITS (2014)
Update on Typical and Atypical Antipsychotic Drugs
Herbert Y. Meltzer
ANNUAL REVIEW OF MEDICINE, VOL 64 (2013)
The Potential of HDAC Inhibitors as Cognitive Enhancers
Johannes Graeff et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 53, 2013 (2013)
A long-term, phase 2, multicenter, randomized, open-label, comparative safety study of pomaglumetad methionil (LY2140023 monohydrate) versus atypical antipsychotic standard of care in patients with schizophrenia
David H. Adams et al.
BMC PSYCHIATRY (2013)
Preclinical models of antipsychotic drug action
Jose L. Moreno et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2013)
Repressive Epigenetic Changes at the mGlu2 Promoter in Frontal Cortex of 5-HT2A Knockout Mice
Mitsumasa Kurita et al.
MOLECULAR PHARMACOLOGY (2013)
Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents
S. Miyamoto et al.
MOLECULAR PSYCHIATRY (2012)
An epigenetic blockade of cognitive functions in the neurodegenerating brain
Johannes Graeff et al.
NATURE (2012)
HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity
Mitsumasa Kurita et al.
NATURE NEUROSCIENCE (2012)
Epigenetic protein families: a new frontier for drug discovery
Cheryl H. Arrowsmith et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Decoding the Signaling of a GPCR Heteromeric Complex Reveals a Unifying Mechanism of Action of Antipsychotic Drugs
Miguel Fribourg et al.
CELL (2011)
A Multicenter, Inpatient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients With DSM-IV Schizophrenia
Bruce J. Kinon et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2011)
Metabotropic glutamate receptors: From the workbench to the bedside
E. Nicoletti et al.
NEUROPHARMACOLOGY (2011)
Metabotropic glutamate mGlu2 receptor is necessary for the pharmacological and behavioral effects induced by hallucinogenic 5-HT2A receptor agonists
Jose L. Moreno et al.
NEUROSCIENCE LETTERS (2011)
Antagonist Functional Selectivity: 5-HT2A Serotonin Receptor Antagonists Differentially Regulate 5-HT2A Receptor Protein Level In Vivo
Prem N. Yadav et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Modeling the Positive Symptoms of Schizophrenia in Genetically Modified Mice: Pharmacology and Methodology Aspects
Maarten van den Buuse
SCHIZOPHRENIA BULLETIN (2010)
Group II metabotropic glutamate receptors and schizophrenia
Jose L. Moreno et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2009)
HDAC2 negatively regulates memory formation and synaptic plasticity
Ji-Song Guan et al.
NATURE (2009)
Psychedelics and schizophrenia
Javier Gonzalez-Maeso et al.
TRENDS IN NEUROSCIENCES (2009)
Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039)
Matthew J. Fell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2008)
Identification of a serotonin/glutamate receptor complex implicated in psychosis
Javier Gonzalez-Maeso et al.
NATURE (2008)
The mGlu2 but not the mGlu3 receptor mediates the actions of the mGluR2/3 agonist, LY379268, in mouse models predictive of antipsychotic activity
M. L. Woolley et al.
PSYCHOPHARMACOLOGY (2008)
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial
Sandeep T. Patil et al.
NATURE MEDICINE (2007)
Hallucinogens recruit specific cortical 5-HT2A receptor-mediated signaling pathways to affect behavior
Javier Gonzalez-Maeso et al.
NEURON (2007)
Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice
Noelia V. Weisstaub et al.
SCIENCE (2006)
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
JA Lieberman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Enhanced cocaine responsiveness and impaired motor coordination in metabotropic glutamate receptor subtype 2 knockout mice
Y Morishima et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice
WPJM Spooren et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Characterization of receptor-mediated [35S]GTPγS binding to cortical membranes from postmortem human brain
J González-Maeso et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2000)
Share Paper
